Wednesday, August 17, 2011

New Drug May Relieve Severe, Tough-to-Treat Gout


The injectable drug pegloticase offers relief to some patients, but carries risk of serious side effects

For some gout patients afflicted with a particularly severe, crippling form of the disease who find standard treatments either intolerable or ineffective, a recently approved alternative appears to afford relief.

A new injectable treatment called pegloticase (brand name Krystexxa) has no effect on most severe gout patients, but researchers say that for the roughly four in 10 patients who do respond positively, the improvement can be significant.

Use of pegloticase was approved by the U.S. Food and Drug Administration in September 2010.

However, the treatment is expensive and the study found a high rate of side effects, some extremely serious, suggesting that health providers have to weigh the costs and benefits on a case by case basis.

"What we're focusing on here are the approximately 3 percent of gout patients who have the most advanced form of disease," said study senior author Dr. Michael A. Becker, professor emeritus of medicine at the University of Chicago.

"About 80 percent of the time these patients are intolerant of the long-standing medication for gout, allopurinol," Becker explained. "For the other 20 percent, the medication either just doesn't have sufficient efficacy or takes too long to take effect.

"So pegloticase is clearly a niche agent designed specifically for these worst cases," Becker said. "It is an expensive alternative requiring carefully monitored intravenous infusions for a prolonged period of time. And there is a potential for infusion reactions, which can be -- although usually aren't -- severe.

"But the bottom line is that this treatment offers hope for people who have been deemed otherwise not amenable to treatment with conventional agents," he concluded.

Savient Pharmaceuticals, which has licensed the exclusive rights to technology relating to pegloticase, funded the study and had input into it.

The study authors noted that approximately 6 million men and women in the United States suffer from some form of gout, an illness that stems from an inability of the body to adequately dispose of uric acid accumulation. Over the last two decades the number of Americans who struggle with the disease has gone up by roughly 50 percent.

For such individuals, mounting uric acid levels give rise to tiny needle-like crystal formations, which in turn lodge in joints and tissues (most notably the big toe), causing inflammation and frequently debilitating pain.

Since 1966, orally administered allopurinol (Lopurin, Zyloprim) has been the treatment of record, helping many patients by lowering the production of uric acid while draining out unsustainable deposits through the kidneys. A second oral treatment option, called febuxostat (Uloric) was approved two years ago.

But for a small minority of patients, the pills either don't work, work too slowly or prompt severe side effects. Their gout can lead to joint disease, deformity, chronic pain, disability and diminished quality of life. And for such individuals there has been no "plan B."

For some of these patients, Becker explained, bi-weekly (every two weeks) intravenous infusions of pegloticase containing a modified version of a pig enzyme called "uricase" (lacking in humans) work by quickly converting uric acid into an alternate and easily excretable fluid.

To see how effective this novel approach might be, the study authors conducted two six-month trials in tandem, involving a final total of 212 patients with severe, chronic and previously untreatable gout who were being cared for at 56 different rheumatology facilities throughout the United States, Canada and Mexico.

Patients were randomly divided into three groups: one to receive 8 milligrams of pegloticase bi-weekly; a second to receive the drug once a month; and the third placed on injectable saline (a placebo).

The result: all patients receiving pegloticase experienced a rapid drop in their uric acid levels to ranges considered normal. However, in some cases the uric acid decline was temporary, the investigators found.

The study indicated that the new treatment will not help all of the estimated 120,000 to 180,000 Americans with this most severe type of gout. In fact, the medication appeared to elicit an all-or-nothing response, greatly helping some patients while having almost no effect on others.

Ultimately, the research team found that 42 percent of the bi-weekly pegloticase patients maintained normal uric acid levels for a minimum of 80 percent of the half-year study period. The same was true among 35 percent of the monthly pegloticase patients. Those given saline solutions saw no improvement at all.

Overall, the quality of life went up among both sets of pegloticase patients, as did mobility and function; there was also a reduction in pain. What's more, many of the lumps typically associated with long-term gout (called "tophi") resolved in roughly 40 percent and 20 percent of the bi-weekly and monthly pegloticase patients, respectively.

However, the authors said 90 percent of pegloticase patients experienced at least one side effect, most commonly a brief flare-up of gout. Such flare-up side effects are also a common feature among allopurinol patients in the immediate period following treatment launch.

More seriously, about one-quarter of the bi-weekly pegloticase patients and 42 percent who had monthly injections experienced infusion-related immune responses at the drug injection site. In 5 percent to 8 percent of patients, the reaction was serious, and five patients experienced anaphylaxis.

Dr. Tuhina Neogi, an associate professor of medicine at Boston University School of Medicine, said: "The vast majority of patients can be appropriately and adequately managed with existing medications. The target for this new approach is clearly not the run-of-the-mill gout patient."

"But for that very small group of patients for whom none of the other options work, or for whom there are intolerances, this is a new way to go," Neogi said.

"And what's worth pointing out," she added, "is that this works by way of a completely different mechanism of action than our existing drugs. Rather than turning off the uric acid faucet or pulling open a drain, this drug goes in there like a bucket and simply removes the stuff. So this is truly unique and exciting."

Bladder Cancer Risk Even Higher for Smokers Than Thought


Increase may be due to change in composition of cigarette smoke, researchers suggest

Almost half of all bladder cancers can be attributed to smoking cigarettes, and the risk of bladder cancer has increased significantly for smokers in the past three decades, a new study finds.

Smokers now face a four times higher risk of developing bladder cancer than someone who has never smoked. Thirty years ago, that risk was about three times that of never-smokers.

Even smokers who've quit the habit still face an increased risk -- 2.2 times higher -- than people who've never smoked, though the risk lessens with time.

"The best way to prevent bladder cancer is for people not to smoke," said study author Neal D. Freedman, an investigator at the National Cancer Institute. "Our study emphasizes the importance of preventing smoking initiation, or for smoking cessation for those who already smoke."

More than 350,000 people are diagnosed with bladder cancer each year, according to the study. More than 70,000 of those cases occur in the United States, according to the study. And, although the incidence rates for bladder cancer appear to be remaining stable, the researchers noted that findings from several studies suggested that rates for smokers seemed to be rising.

Tobacco smoking is the most significant risk factor for the development of bladder cancer, and previous estimates were that smoking increased the risk of bladder cancer nearly threefold.

To get a better idea of the current risk, Freedman and his colleagues reviewed data from the National Institutes of Health-AARP Diet and Health Study, which was conducted between 1995 and 2006. The study included 281,394 men and 186,134 women between the ages of 50 and 71. The volunteers lived in one of eight states: California, Florida, Georgia, Louisiana, Michigan, New Jersey, North Carolina and Pennsylvania.

Almost 4,000 men and 627 women were diagnosed with bladder cancer during the study.

The researchers found that current smokers now had four times the risk of developing bladder cancer compared to people who never smoked.

Overall, smoking was attributed to the development of about half of all bladder cancers.

And, the risk of bladder cancer tends to rise with the number of cigarettes smoked, according to Freedman. Even people who smoke one to 10 cigarettes a day have a significantly higher risk of bladder cancer than people who don't smoke, according to the study.

He also noted that while the risk of bladder cancer remains elevated for former smokers, it does go down the longer someone stays off cigarettes.

Freedman said the authors don't know exactly why the risk of bladder cancer has increased for smokers, but they suspect changes in the composition of cigarette smoke. Cigarettes contain less tar and nicotine now, but cigarette smoke is likely have more cancer-causing chemicals such as beta-napthylamine, which is known to cause bladder cancer, suggest the authors.

"Cigarettes may be even more toxic now than they were years ago," said Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society.

"People who consider themselves casual smokers may think they're not getting as many of the bad effects of smoking, but in this study, the impact of smoking increases the risk of bladder cancer dramatically," he pointed out.

Lichtenfeld advised that anyone who smokes should stop, though he acknowledged that doing so isn't easy. "Cigarettes are a very powerful addiction that's difficult to quit."

But, both experts agreed that for preventing bladder and other cancers, as well as for heart health, quitting smoking -- or never starting to smoke -- is one of the best things you can do.

Moderate Drinking May Help Prevent Alzheimer's, Other Dementia


Lower risk of brain impairment seen in those who enjoy alcohol, but don't overdo it, review finds

Drinking moderate amounts of alcohol, especially wine, may lower the risk of dementia, according to a review of previous research.

The team at Loyola University Chicago Stritch School of Medicine analyzed data from more than 365,000 people who took part in 143 studies that were conducted since 1977.

Moderate drinkers were 23 percent less likely to develop dementia, Alzheimer's disease and other forms of "cognitive impairment," a phrase used to describe a decline in thinking skills. Moderate drinking is generally defined as a maximum of two drinks per day for men and one drink per day for women.

On the other hand, heavy drinking (more than three to five drinks per day) was associated with a higher risk of dementia and cognitive impairment, but the researchers said this finding was not statistically significant.

"We don't recommend that nondrinkers start drinking. But moderate drinking -- if it is truly moderate -- can be beneficial," study co-author Edward J. Neafsey, a professor in the department of molecular pharmacology and therapeutics, said in a Loyola University Medical Center news release.

Wine appeared more beneficial than beer or spirits, but that finding was based on a relatively small number of studies, the study authors noted.

The researchers said the protective effect of moderate drinking remained after they factored in age, education, sex and smoking, and that the effects of alcohol were the same in men and women.

They also noted that the association between moderate drinking and reduced risk of dementia and cognitive impairment was statistically significant in 14 of 19 countries, including the United States.

Still, experts in neurological health weren't entirely sold on the findings.

"This study was well-designed and well-executed but falls in the category of epidemiology [population wide, observational studies]," said Dr. Sam Gandy, chair in Alzheimer's Disease Research and professor of neurology at the Mount Sinai Alzheimer's Disease Research Center, Mount Sinai School of Medicine in New York City. "There are at least a dozen reports such as this, touting the beneficial neurological effects of alcohol. Each report brings calls and visits from patients, interested in what advice they can take away and apply to their own lives."

Gandy said that proof that moderate drinking helps curb dementia rates could only come from a prospective, randomized clinical trial -- something that hasn't happened yet. "Until there are some randomized clinical trial data, no patient guidance is warranted," he said.

Another expert agreed. Dr. James Galvin, director of the Pearl Barlow Center for Memory Evaluation and Treatment at NYU Langone Medical Center in New York City, said that there is growing evidence of a beneficial effect of moderate drinking on dementia, but "we should not rush out to buy bottles of Merlot, Cabernet or Pinot just yet."

And he added that the brain-healthy effects of moderate drinking noted in studies might just be a marker for an overall healthy lifestyle. "The Mediterranean diet with whole grains, fresh fruit and vegetables, olive oil and moderate red wine also reduces the risk of dementia, as does exercise, social engagement, mental activities and an optimistic outlook on life," Galvin said. "It is clear that heart healthy behaviors are also brain healthy behaviors."

For their part, the researchers said that it's not clear why moderate drinking may reduce the risk of dementia and cognitive impairment, but one premise suggests that alcohol might improve blood flow in the brain and thus brain metabolism, the researchers said. And they offered up another theory, that small amounts of alcohol may make brain cells more fit by slightly stressing them and increasing their ability to cope with major levels of stress that can eventually cause dementia.

Five Genes May Be Tied to Lethal Prostate Cancer


Identifying men with aggressive disease can help customize treatment, researchers say

In what may be a diagnostic advance, U.S. and Swedish researchers have linked five inherited genetic mutations to the development of a particularly aggressive and deadly form of prostate cancer.

The findings could someday lead to development of an easy-to-administer blood test to screen for such mutations to help physicians assess the long-term risk faced by newly diagnosed prostate cancer patients, the researchers suggested.

"The ability to distinguish patients at elevated risk for having aggressive, life-threatening prostate cancer at the time of diagnosis could improve care for the subset of cases most likely to benefit from aggressive therapy and help avoid over-treatment of patients whose tumors are likely to remain indolent," the study team, led by Janet L. Stanford, co-director of the Fred Hutchinson Cancer Research Center's program in prostate cancer research
At issue are longstanding concerns about unnecessary over-treatment of many prostate cancer patients who actually face a relatively low risk for fast disease progression and death. Because treatment can bring about undesirable side effects, such as sexual impotence and urinary incontinence, an effort has been under way to achieve a more personalized assessment of a patient's particular prognosis after diagnosis.

"Biomarkers that could distinguish between patients with indolent vs. more aggressive tumors are urgently needed," Stanford said in a journal news release. "The panel of markers we've identified provides the first validated evidence that inherited genetic variants play a role in prostate cancer progression and mortality. Ultimately these markers could be used in the clinic, along with other known predictors that are used to assess tumor aggressiveness, such as a high Gleason score, to identify men with a high-risk profile."

The authors, looking for genetic differences that could highlight risk differences, gathered blood samples from more than 1,300 prostate cancer patients living in the Seattle region. All were between the ages of 35 and 74 when diagnosed.

DNA analyses of the samples were compiled with those of nearly 2,900 Swedish prostate cancer patients.

The result: Five single-letter mutations (or SNPs) were isolated among the patients' "DNA alphabet" as having a significant bearing on prostate cancer progression in terms of affecting cell death, tumor growth, inflammation, androgen hormone levels, blood-vessel development and bone density.

Patients found to have at least four out of the five cited SNP mutations appeared to face a 50 percent higher risk for dying from their disease compared with those who carried two or fewer of the mutations.

William Phelps, program director of translational and preclinical cancer research at the American Cancer Society, said the push to develop more revealing diagnostic tools is driven by an acknowledgement that current treatment options can debilitate patients.

"If the treatments we had for prostate cancer were very tolerable or very safe you would probably treat everybody," he explained. "But the treatments we have available today are less than ideal."

"So certainly we can try to improve treatment," Phelps noted. "But at the same time we can also try to improve ways to identify patients who are more likely to progress rapidly from those likely to be very slow going, so we can reserve treatment for only those instances when it's really necessary."

If there are markers that better define the men whose cancer is most likely to progress, "that would certainly prove very useful in the current climate," he said.

More Kids Hospitalized for Flu, Skin Infections


Children accounted for 17 percent of all U.S. hospital stays in 2009


There was a dramatic increase in the number of children's flu-related hospital stays in the United States between 2000 and 2009, a federal agency says.

Over that time, flu rose from 65th to 10th in the ranking of reasons why children aged 17 and younger go to the hospital, according to a report from the Agency for Healthcare Research and Quality (AHRQ).

The agency also found that skin infections rose from 13th to 7th in the ranking.

In 2009, pneumonia, asthma, acute bronchitis and mood disorders (depression and bipolar disorder) were the leading conditions that led to hospital stays for those aged 17 and younger.

Children accounted for one out of every six hospital stays in 2009 and 9 percent ($33.6 billion) of total hospital costs that year. About 72 percent of children who required hospitalization in 2009 were infants younger than 1, the AHRQ said.

Compared with other hospitalizations in 2009, a child's average hospital stay was shorter (3.8 days vs. 4.6 days) and less expensive ($5,200 vs. $9,200).


The Fattier Your Heart, the Greater Your Heart Disease Risk


Study links buildup of this hidden fat to heart threat, even in people without symptoms


The amount of hidden fat that collects around the heart may be a stronger indicator of cardiac disease risk than a bulging waistline or flabby thighs, a new study reports.

Heart fat hidden behind the rib cage -- known as pericardial fat -- appears to promote irregular plaque build-up along coronary artery walls that causes atherosclerosis and can trigger heart attacks, the leading cause of death in the United States, according to the study.

"It turns out there are specific areas around the heart where hidden fat seems to be promoting coronary disease, even in people without symptoms," said senior study author Dr. David Bluemke, director of radiology and imaging sciences at the National Institutes of Health Clinical Care.

"This is chest fat you'd never see by looking at someone," he added.

Pericardial fat is linked to being overweight or obese, according to the study

The findings are from the ongoing Multi-Ethnic Study of Atherosclerosis (MESA), a study of 6,800 participants aged 45 to 84 from six communities around the country who had no heart disease at enrollment. In this study, researchers looked at a smaller slice of the volunteers: 89 women and 94 men with an average age of 61 who, although most were overweight, were representative of the general population.

To look for signs of heart disease, the research team used noninvasive MRI to screen for plaque on the walls of the coronary artery and compared it with CT scans of heart fat volume. The NIH-sponsored study highlighted three main findings:

  • In people with no symptoms of coronary artery disease, the fat volume of the membrane around the heart is closely associated with the heart artery-clogging plaque found on the MRIs.
  • This pericardial fat appears to be more strongly related to coronary artery plaque buildup than is body mass index (a measure of obesity) or waist circumference.
  • Examining coronary artery walls through MRIs and CT heart fat scans may be useful in assessing the risk of heart disease.

High-risk patients with chest pain and known coronary risk factors such as obesity should have a traditional angiogram or advanced diagnostic procedures, said Bluemke. "However, low or intermediate risk patients may eventually benefit from understanding that fat deposits around the heart increase their risk of coronary disease," he said.

And while MRI was used as the "gold standard" for NIH research on fat distribution and the dangers of obesity, the expensive procedure isn't necessary in typical patient screening for cardiac risk, Bluemke added.

Bluemke said CT scans are one of the fastest growing medical procedures in the country and may increasingly be used to evaluate coronary artery disease. Scanning often provides data on calcium in the heart vessel, and can calculate a 'fat score' index for tissues around the heart as a best practice procedure that could save lives, he said.

"Two-thirds of the population is overweight or obese and at risk of coronary artery disease and plaque buildup," said Bluemke, noting that extra fat forms "preferentially" in vulnerable areas of the heart of typical overweight patients. "This research says we should be telling doctors about the amount of fat in a patient's chest that shows up on a CT scan, but cannot be seen from outside the body and was previously ignored."

The U.S. Centers for Disease Control and Prevention has declared obesity a national epidemic and a major contributor to the leading causes of death in the United States, including heart disease. Slightly more than one adult in three is obese, and one child in six is obese, the CDC reports.

Dr. Gregg Fonarow, professor of cardiology at UCLA, agrees that CT scans may eventually help doctors determine who is most vulnerable to cardiovascular disease. However, he cautions patients not to rush out for expensive and unnecessary scans or MRI screenings just to find hidden heart fat that might be temporary or not pose a long-term problem.

"The research is really to generate new knowledge and information, not to be a risk predictor or screening tool for the general population," said Fonarow.

An interesting finding is the volume of fat around the heart being positively related to the plaque burden in asymptomatic men and women, most of whom need to shed a few pounds, Fonarow said: "This shows a new reason why overweight people have a higher rate of cardiovascular risk and gives the public another reason to maintain a healthy and active lifestyle."



Epileptic boy's book helps raise money for seizure dog


Evan Moss, 7, wrote 'My Seizure Dog,' which has earned enough in donations to help buy a service dog for himself — and four more kids

Evan Moss’ seizures come quietly in the night. When they strike, the 7-year-old’s parents have to give him medicine to make them stop — or risk brain damage. But to do that, they have to know they are happening. Lisa and Rob Moss live in fear of missing one.

The seizures are so silent that even if Rob and Lisa sleep in the next room with a baby monitor to listen, they can’t hear them, so Evan sleeps with them in their bed. “We go through life pretty much not well-rested and with a strong addiction to caffeine,” says Lisa Moss.

But a service dog, specially trained to detect seizures and alert Evan’s parents could help insure that Rob and Lisa don’t miss a seizure, and also make it possible for Evan to sleep in how own bed. The catch? A dog like that costs about $13,000.

To raise the money for a dog for Evan, who has a genetic disorder and epilepsy, the family discussed the usual options: a 5K run, a dinner with a band, a lemonade stand.

As almost an afterthought, they came up with the idea of self-publishing a short book Evan had written as part of his application for the dog. Initially, they modestly hoped maybe they could sell 150 at $10 apiece. But Evan has now sold 10 times that many copies of the 26-page “My Seizure Dog” and counting. As it turns out, none of the profits from book sales needs to go toward the cost of the dog, because donations alone have topped $26,000 — more than twice what the Alexandria, Va., boy Evan needed for his dog. The additional thousands of dollars, plus proceeds from the book, will make up the difference between what four other children’s families have raised and the cost of their service dogs.

Not a single drop of lemonade ever had to be sold.

A July 24 book-signing drew an estimated 650 people to a local coffee shop, and at one point Evan’s book ranked 125th in sales among all the millions of books on Amazon.

Evan, a rising second-grader whose favorite part of the school day, except maybe recess, was “writer’s workshop,” isn’t fazed by the attention.

“It feels pretty nice,” he said Thursday morning before his mom, Lisa, took him to day camp.

Evan’s dog will be trained by the nonprofit 4 Paws for Ability and will be ready for the family to pick up next June. It will be either a poodle or a poodle mix, Lisa Moss says, because poodles are less likely to aggravate her dog allergy.
The theory is that seizure dogs can pick up on a scent related to a chemical change in the body that precedes a seizure, says Moss who, along with her husband

which helps families around the world track their children’s seizures and medications.

Evan’s dog hasn’t yet been selected by 4 Paws, so the Mosses don’t know how it will alert them to an impending seizure. Some dogs bark, others nudge parents, says Karen Shirk, the nonprofit’s founder. “Each dog has their own way of getting attention,” Shirk says.

Still, Lisa Moss says, “that’s a really big task to put on an animal. At the beginning, we’re basically going to have a boy and a dog in our bed. At some point, Evan will be back in his own bed with a dog.”

Evan’s parents first recognized that he was having a seizure when he was a month old, although Rob Moss says he could have been having them since birth.

Evan was diagnosed with a rare genetic disease called tuberous sclerosis complex, which causes benign tumors to grow in the brain and other vital organs, such as the kidneys. Because of tumors in the brain, most patients also have epilepsy. By age 4, Evan was having 300 to 400 seizures a month, but after surgery to remove the brain tumors, he was seizure-free for two years before they returned.

According to the National Institutes of Health, tuberous sclerosis affects 25,000 to 40,000 people in the United States and 1 million to 2 million worldwide. With proper medical care, most can expect to have a normal life expectancy.

Most cases occur as a result of spontaneous mutation in one of the genes that cause the disease, so they’re not passed from parent to child. But children also can inherit the disease from an affected parent so “it’s possible that one of us has it,” Rob Moss says, noting that some people with mild cases aren’t diagnosed until adulthood. To be on the safe side, he added, Evan’s big sister, 9-year-old Aria, will undergo genetic testing when she’s older.

Evan won’t get his dog until next summer, but he’s already making plans to write “My Seizure Dog 2” after he gets his new companion.